Amgen (NasdaqGS:AMGN) made considerable strides in its oncology portfolio, as evidenced by the successful interim results for ...

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...

In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell ...

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...

WASHINGTON, D.C. - The Lawyer’s Committee for Civil Rights Under Law has filed a brief here April on behalf of the Southern ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

No new safety signals were identified for Imfinzi in patients with LS-SCLC. The proportion of patients with adverse events leading to discontinuation of study treatment was 16.4% in the Imfinzi arm.

An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any ...

ST-001, an intravenous nanoformulation of fenretinide, will be evaluated in a phase 1a/1b small cell lung cancer trial.

Small-cell lung cancer (SCLC) is the most aggressive type of lung cancer. Each year in the U.S., about 30,000 to 35,000 people are diagnosed with it. For most, it has already spread to distant ...